Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
Excess mortality rates in the U.S. remain high, despite a steady decline since mid-December.
Chasity’s story stands in hopeful defiance of a typically grim acute lymphocytic leukemia prognosis. In this case, CAR T cell therapy has proven to be a uniquely viable option.
South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located. Aridis Chief Executive Officer Vu Truong believes his company has a better solution – an inhaled antibody.
The findings from Finerenone’s study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine.
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.